Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that …
Myriad Genetics Inc. (MYGN) reported first quarter EPS of $0.31 Tuesday morning, which surpassed analysts' expectations of $0.27. Myriad Genetics climbed until mid-morning Tuesday and advanced further late in the afternoon. …
NASDAQ: MYGN investors should contact the Shareholders Foundation ... and other legal related news to the …
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and …